Drug intelligence / Profile preview

OyaGen-Vif-Env-HIV

Development stage: Preclinical
Lead developer: OyaGen
Modality: Small Molecules
Administration: Oral, Vaginal

Overview

OyaGen-Vif-Env-HIV is a preclinical drug development program by OyaGen aimed at treating HIV-1 infection. The program utilizes a dual-targeting approach, simultaneously inhibiting the Viral infectivity factor (Vif) and the Envelope (Env) proteins. Vif is a critical accessory protein that HIV uses to counteract the host's natural antiviral defense mechanism, specifically the APOBEC3G enzyme. By inhibiting Vif, the drug allows APOBEC3G to hypermutate the viral genome, leading to the production of non-infectious virus particles. The simultaneous targeting of the Env protein, which is essential for viral attachment and entry into host cells, is intended to provide a synergistic antiviral effect and increase the genetic barrier to viral resistance.

Targets

Vif (HIV-1 Vif)

Beyond the preview

Go deeper on OyaGen-Vif-Env-HIV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OyaGen-Vif-Env-HIV.

Explore the full profile